Clinical studies with silymarin: fibrosis progression is the end point.
about
Evaluation of antioxidant activity of Manihot esculenta Crantz in wistar ratsHepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats.Silymarin treatment of viral hepatitis: a systematic review.Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis.Effects of Nigella sativa L. and Urtica dioica L. on lipid peroxidation, antioxidant enzyme systems and some liver enzymes in CCl4-treated rats.
P2860
Clinical studies with silymarin: fibrosis progression is the end point.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Clinical studies with silymarin: fibrosis progression is the end point.
@en
Clinical studies with silymarin: fibrosis progression is the end point.
@nl
type
label
Clinical studies with silymarin: fibrosis progression is the end point.
@en
Clinical studies with silymarin: fibrosis progression is the end point.
@nl
prefLabel
Clinical studies with silymarin: fibrosis progression is the end point.
@en
Clinical studies with silymarin: fibrosis progression is the end point.
@nl
P356
P1433
P1476
Clinical studies with silymarin: fibrosis progression is the end point.
@en
P2093
P304
P356
10.1053/JHEP.2001.22340
P407
P577
2001-02-01T00:00:00Z